Clinical Trials
5 trialsNCT07217587 2026-05-08
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06765161 2025-07-29
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Clinique Neuro-Outaouais
Phase 3 Recruiting
NCT06587867 2024-09-19
Seronegative Myasthenia Gravis - Efgartigimod IV
University Health Network, Toronto
Phase 3 Recruiting
NCT03770403 2023-07-14
ADAPT+
argenx
Phase 3 Completed
NCT03669588 2022-02-08
ADAPT
argenx
Phase 3 Completed